Spent my entire 28 year career on Wall Street with over a decade at Bear Stearns. No "Wall Street Titan" in real life but WST is an alias that I've used for years on Yahoo so I use it when I write on SA. I have gained a significant amount of knowledge regarding the stem cell sector over the years and have recently launched a premium service covering this exciting area.
W. (Ed) Wijaranakula has been a portfolio manager for over 15 years. He has a Ph.D. in Electronic Materials and has worked with Intel, Taiwan Semiconductor, Texas Instruments, and other tech companies in the Silicon Valley, during his professional career. He was also involved with industry research projects at MIT, NC State and the University of Washington. His investment research expertise includes biotech, commodities and currencies. He has published over 600 articles and holds 12 U.S. and international patents.
Slingshot Insights is the first crowdfunded expert network and due diligence community. Members use our suite of tools to cut through the noise and Become the Smart Money. We provide you affordable access to Experts and Management Teams so that you can make informed investment decisions. By grouping investors around project ideas they care about, we pass along significant savings without compromising on quality.
I am a Ph.D. Geneticist with more than 20 years post-graduate working experience in a variety of laboratory settings. I have experience and direct expertise with Genetics, Population Genetics, Biologically-based Chemistry, Molecular Biology and Methods Development and Validation.
My biggest interests for speculative investments are in biotech and nanotech arenas - especially in developmental stage and pre-clinical stage biomedical companies.
Founder, CEO and managing director of Vailshire Capital Management, LLC, in Colorado Springs.
Managing director of Vailshire Partners, LP: a multi-strategy "two-pronged" hedge fund seeking present value, future growth, and current income through an active safe options strategy. The fund frequently sells covered calls and naked puts to earn generous income and profit from market volatility. As a physician, a strong emphasis is placed on health care, pharmaceutical and biotech equities.
Retired on June 30, 2015 from practicing medicine as a Diagnostic and Interventional Radiologist in Colorado Springs, CO.
Currently a full-time investment professional, managing Vailshire Partners, 30+ separately managed accounts via Vailshire Capital Management, as well as, working as an "emerging manager" for a fund-of-funds based in New York.
Biotechnology professional with a diverse scientific background and detailed knowledge in many therapeutic areas such as monoclonal antibodies, immunotherapies and antivirals. I have a personal interest in finance, investing and global markets. My investing strategy is mainly long-term/retirement and exploring avenues to maximize wealth in retirement. My analysis is focused on stocks and exchange traded funds (ETFs) while exploring niche opportunities such as derivative trading in the form of covered call options. I write opportunistic weekly, bi-weekly and/or monthly out-of-the-money covered call options on an regular basis to augment my portfolio returns and to accumulate a larger cash position to buy during periods of weakness. I also have an interest in personal finance (529 plans, FSAs, HSAs, Roth IRAs, etc.) and serve as a contributor in this area for WalletPath. Education: Masters of Science in Molecular and Cellular Biology Bachelor of Science in Biological Sciences
Financial markets have fascinated me since childhood. I strive to combine my education in biology, math and history with common sense to find winning trades.
To identify good investments and the right time to enter/exit them, I draw on all financial disciplines that could be helpful. The following is a non-exhaustive list that inform my decisions: Finances of a company, market condition, who owns it, what insiders are doing, analysis of trading behavior, option positions, short interest, public perception, social media, retail involvement, deep valuation of assets and patents, debts and obligations etc.
Btw, my screen name refers to the popular MODIS satellite package in polar orbit around earth. It's mission is to daily photograph the entire planet in several optical bands. This data that is then made available to researchers like biologists, which is how I know about it. It is my inspiration to try see things as they really are.
MODIS also reminds me of my favorite quote from Mr. Buffett: "It's easier to make up a lost opportunity, than to recover from a loss." The instrument moves on, seeing new things; it doesn't get stuck. Capital is a precious resource, so every trade deserves to be as perfect as you can make it.
I am an independent senior pension and investment analyst with years of experience working on the buy and sell-side. I have researched and invested in traditional and alternative asset classes at two of the largest public pension funds in Canada, the Caisse de dépôt et placement du Québec (Caisse) and the Public Sector Pension Investment Board (PSP Investments). I've also consulted the Treasury Board Secretariat of Canada on the governance of the Federal Public Service Pension Plan (2007) and been invited to speak at the Standing Committee on Finance (2009) and the Senate Standing Committee on Banking, Commerce and Trade (2010) to discuss Canada's pension system. You can follow my blog posts on your Bloomberg terminal and track me on Twitter (@PensionPulse) where I post many links to pension and investment articles as well as my market thoughts and other articles of interest. Please remember to support my efforts by clicking on the ads on the blog but more importantly by contributing via PayPal clicking on the buttons below. Anyone can contribute any amount at any time (all tips are greatly appreciated) but institutional investors are kindly requested to support this blog via an annual subscription of $500, $1000 or $5000 CAD (third option includes specialized consulting mandates). For all inquiries and comments, email me at LKolivakis@gmail.com.
Having always been a learning machine, I speak five languages, have worked as a sales agent, project manager, translator, computer consultant, software engineer, built a house with my own hands, published books and essays on literature, philosophy and art, have written for magazines of various kinds in different countries.
After retiring early in 2004, little by little, I have become a fund manager for some friends and myself, following the principles of value investing laid out by Benjamin Graham, Phil Fisher, Charlie Munger and Warren Buffett. You can read about my thoughts on a suitable portfolio structure for early retirees here.
My articles should not be considered to be any kind of investment advice. What suits me well is not necessarily good for others, as successful investing is somewhat like a marriage: If only one is perfect, the marriage won’t work. So please do your own research and remember Benjamin Graham's advice: “The investor’s chief problem — and even his worst enemy — is likely to be himself.”
I sincerely hope that my readers will ignore the Performance calculations provided by Seeking Alpha (although only to Pro subscribers, I believe). For reasons unknown to me, some of my European stock picks seem to be tracked inaccurately by Seeking Alpha's system. Spin-offs are not included in total return calculations and many of my correction requests didn't receive any answer at all. Moreover, my time frame almost never is as short as only 1 year (the maximum included in Seeking Alpha's table) and personally I consider the 1 year performance of my stock picks to be close to meaningless.
I am a pharmacist for a large research hospital system based in Ohio. I generally am interested in the pharmaceutical industry as well as large income producing companies. I am long ATHX, PFE, MNTA, and ABLYF
I believe that there is almost no way I can retire comfortably with the standard method of Social Security plus maxed 401k using managed mutual funds. I need to make a significant gain at some point to change the equation. This means more risk, but hopefully a controlled amount can yield a retirement worth living.
Spencer Osborne is founder of Satellite Standard Group [SSG], and a partner of Sirius Buzz (http://siriusbuzz.com/). Sirius Buzz covers the satellite radio industry as well as companies that do business in this sector. Sirius Buzz provides information and opinion to readers with an interest in the sector from an investment, as well as consumer perspective.
Along with his work in the media sector, Spencer covers various equities that interest him and writes about these equities from a unique and "out of the box" perspective. Over the years Spencer has built a network of resources within the sectors he writes about. His opinion and insight is oft referred to and sought after by analysts.
Founder of Slingshot Insights, a company that works to provide retail investors access to professional grade investment research tools not readily at their disposal. As a former analyst at a large hedge fund, I found that as I began trading individual stocks on my own, I missed the research tools available to me when I worked for a large institution. The company was born from this idea and my desire to have access to a resource like SI.
www.SlingshotInsights.com Join for free today and check out our cartoon where "Investor Man" Becomes the Smart Money (and explains what Slingshot Insights can do for your diligence process)
Prior to starting Slingshot Insights, I was an analyst at a large hedge fund where I focused on the pharmaceutical industry creating investment theses driven by primary research. I remain a very active investor in a variety of stocks.
Motto: I invest in undervalued (i.e. cheap) well-established companies trading at a below market multiple.
The companies that I invest in are large stable companies with proven track records. My goal is the highest total return possible with the least amount of risk.
Professional Background: I am a healthcare practitioner with extensive experience in the pharmaceutical sector. I have a passion for investing honed over the past twenty years through various market cycles.
Editor for The Biotech Forum, the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade.
Please go to biotechforumsa.com for more on the Biotech Forum service available through SeekingAlpha. For Free Investment Reports on a variety of topics go to bretjenseninvests.com
Peter Xenopoulos is a mathematics and economics student at Pomona College. He is particularly interested in the healthcare, biotech and IT sectors. You can reach his linked profile here: https://www.linkedin.com/in/peterxenopoulos
I am a financially motivated undergraduate student interested in investing. I have a background in investing, consisting of several courses on finance and six years of experience.
Keith began his career as a research scientist (developmental biology, biochemistry, molecular biology) at the Australian National University, University of Oxford (UK), the Max Planck Institute for Biochemistry (Munich, Germany) and finally Macquarie University (Sydney) where he held a Chair in Biology and established the Centre for Analytical Biotechnology. Pioneering the area of proteomics (with Marc Wilkins in his group coining the term), Keith established the world’s first government-funded Major National Proteomics Facility (Australian Proteome Analysis Facility) which was involved with industrialising protein science.
Keith left academe with his team to found Proteome Systems Ltd in 1999 to commercialise proteomics. The company had a strong focus on intellectual property, engineering/technology and bioinformatics. As CEO he led the company to ASX listing in 2004. Since 2005 Keith has been involved in new business development in biotech, e-health and other emerging technologies. Keith sees climate change and sustainable development as a major issue for humankind and also a major business disruptor/risk and opportunity.
Keith holds a Bachelor Agr Science from the University of Melbourne and a PhD from the Australian National University. He is a Fellow of the Australian Academy of Technological Sciences & Engineering and received an AM (Member of the Order of Australia) for services to the Biotechnology Industry. He has received various industry awards including an Innovation Hero Medal from the Warren Centre for Advanced Engineering.
With 300 scientific papers and many patents written, Keith has a clear view of innovation in the Biotechnology and Climate/Renewable Energy space. He is not a financial advisor but his perspective adds relevance to decision-making concerning feasibility and investment in technology innovation.
Paul has been managing Noble Equity Fund, LP, a healthcare-focused hedge fund, since January of 2008. In addition, he manages Noble Advisors, LLC, a Registered Investment Advisor. Prior to this, he worked on the sell side at Sidoti & Co. and Deutsche Bank covering various industries. Mr. Nouri graduated from Rensselaer Polytechnic Institute, in 2005, with a Bachelors of Science in Finance. He is currently seeking his EMBA at Yale.
6 years in investment banking at Bulge bracket, 2 years at Italian Bank, 1.5 year at Hedge Fund
Engineer, MBA, CFA Charterholder
10 years total in Financial markets
Currently managing personal assets: mainly biotech, banks, value stocks, event situations
Travis primarily invests in smid-cap stocks for long term positions, but partakes in some event driven activity: IPO, biotech run-ups, corporate restructuring, etc. As an investor, he is looking for value stocks that Mr. Market has overlooked (J.Greenblatt). The style with light analysis on trailing-financial statistics, paired with consumer trends, legal review, and CVs.
He utilizes a multifaceted writing and research discipline; a professional background from public school teaching to government investigation. Reviewing SEC forms, SCOTUS decisions, and various law journals lends to supplemental insights for stock analysis.
At the height of 2015 performance, Travis' stock picks placed him in top tiers. Out of all experts, including institutional analysts, he was ahead of approximately 85% of the field. Visit his TipRanks profile for real-time updates.
Website: DIY Stock Investor